[go: up one dir, main page]

MX2012009576A - Formas de rifaximina y usos de la misma. - Google Patents

Formas de rifaximina y usos de la misma.

Info

Publication number
MX2012009576A
MX2012009576A MX2012009576A MX2012009576A MX2012009576A MX 2012009576 A MX2012009576 A MX 2012009576A MX 2012009576 A MX2012009576 A MX 2012009576A MX 2012009576 A MX2012009576 A MX 2012009576A MX 2012009576 A MX2012009576 A MX 2012009576A
Authority
MX
Mexico
Prior art keywords
rifaximin
forms
relates
present
therapeutic methods
Prior art date
Application number
MX2012009576A
Other languages
English (en)
Other versions
MX353827B (es
Inventor
Karen S Gushurst
Donglai Yang
Petinka Vlahova
Jeffrey S Stults
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of MX2012009576A publication Critical patent/MX2012009576A/es
Publication of MX353827B publication Critical patent/MX353827B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a formas polimórficas de rifaximina, a su uso en preparaciones medicinales y a métodos terapéuticos que las utilizan.
MX2012009576A 2010-02-19 2011-02-16 Formas de rifaximina y usos de la misma. MX353827B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/708,836 US8486956B2 (en) 2008-02-25 2010-02-19 Forms of rifaximin and uses thereof
PCT/US2011/024981 WO2011103120A1 (en) 2010-02-19 2011-02-16 Forms of rifaximin and uses thereof

Publications (2)

Publication Number Publication Date
MX2012009576A true MX2012009576A (es) 2012-12-05
MX353827B MX353827B (es) 2018-01-31

Family

ID=44483273

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009576A MX353827B (es) 2010-02-19 2011-02-16 Formas de rifaximina y usos de la misma.

Country Status (21)

Country Link
US (5) US8486956B2 (es)
EP (1) EP2536734B1 (es)
JP (2) JP2013520427A (es)
KR (1) KR20120140244A (es)
CN (2) CN105254647A (es)
AU (3) AU2011218258B2 (es)
BR (1) BR112012020863A2 (es)
CA (1) CA2790332A1 (es)
CR (1) CR20120449A (es)
EA (1) EA201270722A1 (es)
GE (2) GEP20156230B (es)
IL (1) IL221299A (es)
MA (1) MA34058B1 (es)
MX (1) MX353827B (es)
MY (1) MY158992A (es)
NZ (1) NZ601670A (es)
PH (1) PH12012501623A1 (es)
SG (1) SG183188A1 (es)
TN (1) TN2012000414A1 (es)
WO (1) WO2011103120A1 (es)
ZA (1) ZA201206227B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3001996A (en) * 1957-02-08 1961-09-26 Hans S Mannheimer Sulfates and sulfonates of n-tertiary amino alkyl-carboxylic acid amides
EP1698630B1 (en) 2005-03-03 2014-09-03 ALFA WASSERMANN S.p.A. New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
MY158257A (en) 2008-02-25 2016-09-30 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
EP4342465A3 (en) 2008-10-02 2024-06-12 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CN103269587A (zh) * 2010-06-03 2013-08-28 萨利克斯药品有限公司 利福昔明的新形式及其用途
WO2011156897A2 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
EA033370B1 (ru) * 2010-07-12 2019-10-31 Salix Pharmaceuticals Ltd Составы рифаксимина и их применение
EP2616044A1 (en) * 2010-09-13 2013-07-24 Cilpa Limited Pharmaceutical composition
BR112013020265A2 (pt) * 2011-02-11 2017-07-11 Salix Pharmaceuticals Ltd formas de rifaximina e uso das mesmas
AU2012251385A1 (en) * 2011-05-02 2013-11-21 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
JP2014532723A (ja) 2011-11-02 2014-12-08 サリックス ファーマスーティカルズ，リミテッド 過敏性腸症候群（ｉｂｓ）及び感染症を治療するための方法
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
CA2876737A1 (en) 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
KR102190173B1 (ko) 2013-04-12 2020-12-14 알파시그마 에스.피.에이. Ｎｓａｉｄ 투여 및 관련 조성물, 방법 및 시스템
CN103509038B (zh) * 2013-09-30 2016-01-20 浙江思贤制药有限公司 一种新晶型利福昔明ζ及其制备方法
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
CN106795192B (zh) 2014-05-04 2020-06-16 萨利克斯药品公司 Ibs微生物群及其用途
EP3546464B1 (en) 2014-05-12 2020-06-17 Alfasigma S.p.A. Preparation and use of crystalline form tau of rifaximin solvated with degme
WO2016204474A2 (ko) * 2015-06-18 2016-12-22 주식회사대성미생물연구소 리팍시민 결정체를 포함하는 동물 장염 치료용 수의학적 조성물
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN117447487A (zh) * 2022-07-19 2024-01-26 重庆圣华曦药业股份有限公司 一种利福昔明的纯化方法及其在利福昔明片剂中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
DE102004004433A1 (de) 2004-01-28 2005-08-18 Trützschler GmbH & Co KG Vorrichtung an einer Spinnereimaschine, insbesondere Karde, Reiniger o. dgl., zum Aufziehen einer Garnitur auf eine Walze
CN101065385A (zh) * 2004-07-22 2007-10-31 坎布里制药公司 治疗微生物感染的利福霉素衍生物
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
EP1698630B1 (en) * 2005-03-03 2014-09-03 ALFA WASSERMANN S.p.A. New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CA2663776C (en) 2006-09-22 2016-01-26 Cipla Limited Rifaximin in an amorphous form
US20100136125A1 (en) 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
MY144578A (en) * 2007-07-27 2011-10-14 Alfa Wassermann Spa New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009047801A1 (en) 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
MY158257A (en) 2008-02-25 2016-09-30 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US20090324736A1 (en) * 2008-05-07 2009-12-31 Salix Pharmaceuticals, Ltd. Methods of treating bowel diseases by administering a bowel cleanser and an antibiotic
WO2010033179A1 (en) 2008-09-17 2010-03-25 Mylan Laboratories, Inc. Granulates, process for preparing them and pharmaceutical products containing them
JP5756020B2 (ja) 2008-12-10 2015-07-29 シプラ・リミテッド リファキシミン複合体
KR20190000931A (ko) 2009-10-27 2019-01-03 루핀 리미티드 리팍시민의 고형 분산물
EP2401282B2 (en) 2009-12-28 2017-01-04 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
CN103269587A (zh) * 2010-06-03 2013-08-28 萨利克斯药品有限公司 利福昔明的新形式及其用途
WO2011156897A2 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
BR112013020265A2 (pt) * 2011-02-11 2017-07-11 Salix Pharmaceuticals Ltd formas de rifaximina e uso das mesmas

Also Published As

Publication number Publication date
NZ601670A (en) 2014-11-28
HK1179608A1 (zh) 2013-10-04
AU2016269529A1 (en) 2017-01-05
US20100174064A1 (en) 2010-07-08
MY158992A (en) 2016-11-30
CR20120449A (es) 2012-11-29
CN105254647A (zh) 2016-01-20
AU2011218258B2 (en) 2015-11-05
US20160200738A1 (en) 2016-07-14
EP2536734A1 (en) 2012-12-26
TN2012000414A1 (en) 2014-01-30
AU2014246594B2 (en) 2016-09-15
KR20120140244A (ko) 2012-12-28
US9273066B2 (en) 2016-03-01
US9546183B2 (en) 2017-01-17
US8486956B2 (en) 2013-07-16
MX353827B (es) 2018-01-31
BR112012020863A2 (pt) 2016-06-21
IL221299A0 (en) 2012-10-31
GEP20156230B (en) 2015-01-26
MA34058B1 (fr) 2013-03-05
GEP201706745B (en) 2017-10-10
JP2016094416A (ja) 2016-05-26
US20140141081A1 (en) 2014-05-22
US20140179916A1 (en) 2014-06-26
US9034892B2 (en) 2015-05-19
EA201270722A1 (ru) 2013-03-29
CN102834398A (zh) 2012-12-19
ZA201206227B (en) 2018-12-19
AU2011218258A1 (en) 2012-08-30
WO2011103120A1 (en) 2011-08-25
US8569326B2 (en) 2013-10-29
EP2536734B1 (en) 2016-08-31
EP2536734A4 (en) 2013-06-26
AU2014246594A1 (en) 2014-10-30
JP2013520427A (ja) 2013-06-06
CA2790332A1 (en) 2011-08-25
IL221299A (en) 2017-11-30
SG183188A1 (en) 2012-09-27
US20120316334A1 (en) 2012-12-13
AU2016269529B2 (en) 2018-06-07
PH12012501623A1 (en) 2012-10-22

Similar Documents

Publication Publication Date Title
TN2012000414A1 (en) Forms of rifaximin and uses thereof
TN2012000611A1 (en) Formulations of rifaximin and uses thereof
MY158257A (en) Forms of rifaximin and uses thereof
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
IN2012DN01920A (es)
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
NZ629697A (en) Human anti-cd27 antibodies, methods and uses
PH12018501404A1 (en) Forms of rifaximin and uses thereof
WO2012030993A3 (en) Skin compositions and methods of use thereof
ZA201408119B (en) Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
MX349004B (es) Nuevos compuestos.
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
HUE041553T2 (hu) Lizoszomális tárolási betegségek (LSD) kezelése és génterápia
GB201106750D0 (en) Novel compounds
MX366899B (es) Nuevos compuestos.
MX2016008448A (es) Conjugados de var2csa-farmaco.
MY156697A (en) Modified tuberculosis antigens
IN2014DN06104A (es)
PH12014501991B1 (en) Phenicol antibacterials
MX367393B (es) Composiciones antifungicas para el tratamiento de piel y uñas.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX356727B (es) Formulaciones de liberacion modificada de viloxacina.
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
MX2013008559A (es) Derivados de leptina.
WO2012119045A3 (en) Compositions and uses thereof to ameliorate pain

Legal Events

Date Code Title Description
FG Grant or registration